1. Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis

3. The Decade of Atopic Dermatitis

5. SCORAD Assessment of Disease Severity

6. Quality of Life Is Affected by AD

7. How Will Emerging Biologic Agents Affect AD Management?

8. How Will Emerging Topical Agents Affect AD Management?

9. Systemic Therapies

10. Emerging Agents Th2 Pathway Inhibitors

11. Emerging Agents IL-31 Pathway Inhibitor

12. Examining Study Design

13. Proactive Treatment

14. Reactive vs Proactive Treatment

15. Nonlesional Skin in AD Patients is Not Normal

16. Treatment of Pediatric Patients With AD

17. Pediatric AD and Adult AD Have Differences

18. Atopic Association

19. Concluding Remarks

20. Abbreviations

21. Abbreviations